REPHUnknown
Recro Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Recro Pharma, Inc. (REPH), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are REPH insiders buying or selling?
Recro Pharma, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 28 Form 4 filings for REPH: 8 buys ($370.6K) and 20 sells ($8.2M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Mar 17, 2022)
Total Form 4 filings
28
SEC EDGAR
Insider filers
10
Insider buys (8)
$370.6K
Insider sells (20)
$8.2M
Insider sentiment
Net sellingNet insider flow of $7.8M in net selling since January 2018.
Recent REPH insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 17, 2022 | David J Enloe JR | Chief Executive Officer | Purchase | 512 | $1.96 | $1.0K | SEC ↗ |
| Feb 17, 2022 | David J Enloe JR | Chief Executive Officer | Purchase | 571 | $1.77 | $1.0K | SEC ↗ |
| Jan 19, 2022 | David J Enloe JR | Chief Executive Officer | Purchase | 602 | $1.68 | $1.0K | SEC ↗ |
| Dec 23, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 99.4K | $1.55 | $154.2K | SEC ↗ |
| Dec 20, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 50.0K | $1.61 | $80.5K | SEC ↗ |
| Dec 18, 2021 | David J Enloe JR | Chief Executive Officer | Purchase | 617 | $1.61 | $993.37 | SEC ↗ |
| Dec 15, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 50.6K | $1.62 | $81.8K | SEC ↗ |
| Nov 19, 2021 | James Charles Miller | Director | Purchase | 1.0K | $1.69 | $1.7K | SEC ↗ |
| Nov 16, 2021 | Ryan David Lake | Chief Financial Officer | Purchase | 1.2K | $1.65 | $2.0K | SEC ↗ |
| Nov 16, 2021 | David J Enloe JR | Chief Executive Officer | Purchase | 1.7K | $1.68 | $2.9K | SEC ↗ |
| Jun 14, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 466.7K | $2.21 | $1.0M | SEC ↗ |
| Dec 29, 2020 | SCP Vitalife Partners (Israel) II, L.P. | 10% Owner | Sale | 18.8K | $3.17 | $59.7K | SEC ↗ |
| Dec 29, 2020 | SCP Vitalife Partners II LP | 10% Owner | Sale | 56.4K | $3.17 | $178.7K | SEC ↗ |
| Dec 23, 2020 | SCP Vitalife Partners (Israel) II, L.P. | 10% Owner | Sale | 6.2K | $3.03 | $18.8K | SEC ↗ |
| Dec 23, 2020 | SCP Vitalife Partners II LP | 10% Owner | Sale | 18.6K | $3.03 | $56.3K | SEC ↗ |
| Apr 20, 2020 | Geraldine Henwood | President and CEO | Sale | 80.0K | $8.22 | $657.6K | SEC ↗ |
| Apr 20, 2020 | Geraldine Henwood | President and CEO | Sale | 80.0K | $8.22 | $657.6K | SEC ↗ |
| May 21, 2019 | Arnaud Ajdler | Director | Purchase | 40.0K | $9.00 | $360.0K | SEC ↗ |
| May 15, 2019 | Geraldine Henwood | President and CEO | Sale | 144.8K | $8.89 | $1.3M | SEC ↗ |
| May 24, 2018 | Broadfin Healthcare Master Fund Ltd | 10% Owner | Sale | 188.0K | $5.81 | $1.1M | SEC ↗ |
| Mar 15, 2018 | Broadfin Healthcare Master Fund Ltd | 10% Owner | Sale | 200.0K | $10.07 | $2.0M | SEC ↗ |
| Mar 13, 2018 | Michael Berelowitz | Director | Sale | 7.5K | $10.45 | $78.3K | SEC ↗ |
| Jan 8, 2018 | SCP Vitalife Partners (Israel) II, L.P. | 10% Owner | Sale | 1.6K | $8.84 | $14.0K | SEC ↗ |
| Jan 8, 2018 | SCP Vitalife Partners II LP | 10% Owner | Sale | 4.7K | $8.84 | $41.8K | SEC ↗ |
| Jan 5, 2018 | SCP Vitalife Partners II LP | 10% Owner | Sale | 38.8K | $8.88 | $344.7K | SEC ↗ |
Showing the 25 most recent of 28 Form 4 filings for Recro Pharma, Inc..
Most active REPH insiders
- David J Enloe JR5 filings
- SCP Vitalife Partners (Israel) II, L.P.5 filings
- SCP Vitalife Partners II LP5 filings
- AWM Investment Company, Inc.4 filings
- Geraldine Henwood3 filings
Ask anything about REPH insider activity
Use Trabud's AI agent to query Recro Pharma, Inc.'s Form 4 history in plain English — "Show me REPH CEO purchases this year" or compare it against any other ticker.
Open the AI agentREPH insider trading FAQ
Are Recro Pharma, Inc. insiders buying or selling?
Recro Pharma, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 28 Form 4 filings for REPH: 8 buys ($370.6K) and 20 sells ($8.2M). Over the full record that is net selling of $7.8M.
How many insiders trade REPH stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Recro Pharma, Inc.. The most recent filing was accepted on Mar 17, 2022.
Where does Trabud get REPH insider trading data?
All REPH insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.